RightEye

Company Overview

RightEye is a US-based digital health company that leverages eye-tracking technology to detect, diagnose, and monitor neurological and visual disorders. Founded in 2013, the company's platform uses infrared eye-tracking cameras and machine learning algorithms to objectively measure eye movement patterns that serve as biomarkers for various conditions including [Parkinson's disease](/diseases/parkinsons-disease), [Alzheimer's disease](/diseases/alzheimers-disease), concussion, and autism spectrum disorder[@righteye_corp].

RightEye's core proposition is that eye movements provide a window into brain function — subtle abnormalities in saccades, smooth pursuit, fixation stability, and pupillary response can reveal neurological dysfunction years before symptoms become apparent clinically. For Parkinson's disease specifically, characteristic oculomotor abnormalities including slowed saccades, increased error rates on antisaccade tasks, and impaired smooth pursuit have been documented extensively in the literature and are well-positioned for technology-enabled objective measurement[@basnayake2019].

Technology Platform

Eye-Tracking Hardware

RightEye employs:

Company Overview

RightEye is a US-based digital health company that leverages eye-tracking technology to detect, diagnose, and monitor neurological and visual disorders. Founded in 2013, the company's platform uses infrared eye-tracking cameras and machine learning algorithms to objectively measure eye movement patterns that serve as biomarkers for various conditions including [Parkinson's disease](/diseases/parkinsons-disease), [Alzheimer's disease](/diseases/alzheimers-disease), concussion, and autism spectrum disorder[@righteye_corp].

RightEye's core proposition is that eye movements provide a window into brain function — subtle abnormalities in saccades, smooth pursuit, fixation stability, and pupillary response can reveal neurological dysfunction years before symptoms become apparent clinically. For Parkinson's disease specifically, characteristic oculomotor abnormalities including slowed saccades, increased error rates on antisaccade tasks, and impaired smooth pursuit have been documented extensively in the literature and are well-positioned for technology-enabled objective measurement[@basnayake2019].

Technology Platform

Eye-Tracking Hardware

RightEye employs:

• Infrared eye-tracking cameras: High-frequency sampling (up to 250 Hz) for precise temporal resolution of eye movements
• Remote, non-invasive setup: No head-mounted hardware required — subjects sit in front of a screen-based system
• Binocular tracking: Simultaneous measurement of both eyes to detect asymmetries characteristic of neurological disease
• Automated calibration: Rapid calibration procedure suitable for diverse patient populations including elderly and cognitively impaired individuals[@righteye_parkinson]

Oculomotor Tests

The RightEye platform administers standardized oculomotor assessments:

Machine Learning Analysis

RightEye's algorithms:

• Normative database comparison: Patient eye movement profiles compared against age-matched healthy controls
• Disease-specific signatures: Trained models to detect oculomotor patterns associated with specific neurological conditions
• Quantified outputs: Numerical scores for saccadic velocity, error rates, pursuit gain, and other parameters
• Longitudinal tracking: Comparison of individual performance over time to detect subtle change[@macaskill2019]

Parkinson'S Disease Applications

Diagnostic Support

RightEye's oculomotor assessment can support PD diagnosis:

• Early detection: Saccadic abnormalities detectable in prodromal and early-stage PD[@filipowicz2020]
• Objective measurement: Eye-tracking provides quantitative data supplementing clinical examination
• Differential diagnosis: Certain oculomotor patterns may help distinguish PD from other parkinsonian syndromes
• Screening tool: Potential for population-level screening of at-risk individuals[@bharti2020]

Research Applications

The company supports clinical research:

• Biomarker development: Oculomotor metrics as objective endpoints in clinical trials
• Natural history studies: Tracking oculomotor change in untreated and treated PD patients
• Drug mechanism studies: Assessing whether dopaminergic medications improve specific oculomotor deficits[@wilkinson2019]

Patient Monitoring

RightEye's technology enables:

• Disease progression tracking: Objective quantification of oculomotor deterioration over months and years
• Treatment response assessment: Monitoring whether therapeutic interventions improve oculomotor function
• Remote monitoring: Potential for at-home eye-tracking assessment to supplement clinic visits
• Quality of life correlation: Linking eye movement metrics to functional outcomes and quality of life[@armstrong2020]

Clinical Validation

Scientific Basis

Eye movement abnormalities in Parkinson's disease are well-established in the literature:

| Finding | Study | Key Result |
|---------|-------|------------|
| Saccadic slowing | Basnayake 2019 | Peak velocity reduced 20-40% in PD vs controls |
| Antisaccade errors | Armstrong 2020 | Error rate 30-50% in PD vs 10-15% in controls |
| Smooth pursuit impairment | Pretegiani 2018 | Pursuit gain reduced, catch-up saccades increased |
| Predictive saccade deficits | Filipowicz 2020 | Predictive saccades impaired in prodromal PD |

Published Evidence

RightEye's platform and related eye-tracking technology for PD:

• Multiple studies using infrared eye-tracking demonstrate robust PD vs control discrimination using saccadic parameters[@basnayake2019]
• Antisaccade error rates provide high specificity for differentiating PD from essential tremor[@pretegiani2018]
• Prodromal PD patients show measurable oculomotor abnormalities before motor diagnosis[@filipowicz2020]
• Oculomotor metrics correlate with MDS-UPDRS scores and disease duration[@macaskill2019]

Market and Applications

Primary Use Cases

RightEye serves:

FDA Clearances

RightEye has obtained FDA clearance for:

• Eye-tracking concussion detection: System cleared for identifying potential concussion via oculomotor assessment
• Reading assessment: Tools for identifying reading difficulties through eye movement analysis

Competitive Landscape

| Company | Technology | PD Focus | Status |
|---------|------------|----------|--------|
| RightEye | Eye-tracking | Oculomotor biomarkers | Commercial |
| Neuro-Trax | Eye-tracking | Cognition assessment | Commercial |
| RightEye | Eye-tracking | Concussion/ASD | Commercial |
| Occytes | Oculomotor diagnostics | Various | Research |
| Microblink | Eye tracking | Various | Commercial |

RightEye differentiates through:

• FDA clearance: Regulatory-cleared products for specific clinical applications
• Broad neurological coverage: Applicable across concussion, PD, Alzheimer's, and autism
• Automated analysis: Machine learning eliminates need for specialized technicians
• Ease of use: Remote, non-invasive eye-tracking suitable for elderly populations

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)](/proteins/parkin)
• [Oculomotor Abnormalities in PD](/topics/oculomotor-parkinsons)](/proteins/parkin)
• [Digital Health for Neurodegeneration](/topics/digital-health-neurodegeneration)](/diseases/neurodegeneration)
• [Diagnostic Biomarkers for PD](/topics/pd-diagnostics)](/diagnostics)
• [PD Neurotechnology](/companies/pd-neurotechnology)](/companies/pd-neurotechnology)
• [Great Lakes NeuroTechnologies](/companies/great-lakes-neurotechnologies)](/technologies)
• [Charco Neurotech](/companies/charco-neurotech)

References